Sonnet BioTherapeutics (NASDAQ:SONN – Get Free Report) released its earnings results on Thursday. The company reported ($1.56) EPS for the quarter, topping the consensus estimate of ($11.12) by $9.56, Zacks reports.
Sonnet BioTherapeutics Stock Performance
Shares of NASDAQ SONN traded down $0.02 during trading on Thursday, hitting $1.54. The stock had a trading volume of 31,288 shares, compared to its average volume of 230,460. The firm has a fifty day moving average of $1.65 and a two-hundred day moving average of $2.25. Sonnet BioTherapeutics has a 12 month low of $1.41 and a 12 month high of $18.72.
Analysts Set New Price Targets
Separately, Chardan Capital cut their target price on shares of Sonnet BioTherapeutics from $30.00 to $20.00 and set a “buy” rating on the stock in a research note on Friday, December 20th.
Sonnet BioTherapeutics Company Profile
Sonnet BioTherapeutics Holdings, Inc, a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.
Featured Articles
- Five stocks we like better than Sonnet BioTherapeutics
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Upstart’s Uptrend Is Just Getting Started: Its Time to Load Up
- Where Do I Find 52-Week Highs and Lows?
- Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?
- Manufacturing Stocks Investing
- Buffett Buys More Occidental Petroleum—Sticking to His Playbook
Receive News & Ratings for Sonnet BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonnet BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
